Figure 1
From: Development of a novel small antibody that retains specificity for tumor targeting
Schematic diagram for the process of constructing the small antibody and the fusion peptide. (a) The small antibody (the mimetic moiety) was composed of V H FR1 C-10 -V H CDR1-V H FR2-V L CDR3-V L FR4 N-10 . (b, c) The mimetic was conjugated to the C-terminal of wild-type colicin Ia to construct the conjugated peptide, named protomimecin (PMN). (d) The 15% SDS- PAGE migration map of the fusion peptide PMN.